Drug

 

(57) Abstract:

The invention relates to the field of pharmaceuticals, namely, to medicines, and can be used to adjust the chemical composition of food, for example, metabolic disorders in patients with chronic renal failure. The invention lies in the fact that the drug contains polifan and purified, concentrated soy protein, soy isolates at a certain ratio of the initial components. The invention provides for an expansion of the range of drugs used in patients with chronic renal failure. table 2.

The invention relates to medicine, namely to medicines, and can be used to adjust the chemical composition of food, for example, metabolic disorders in patients with chronic renal insufficiency.

Renowned pharmaceutical composition of ranitidine and calcium carbonate (RU application No. 96108250/14 And 61 To 33/10, 30.09.1993). It contains ranitidine in the amount of from 25 to less than 100 mg per dose and calcium carbonate and is used for treatment and prevention of a number of gastrointestinal diseases. Ranitidine imported into R sick suffering from renal diseases.

Known way to protect the stomach from damage to bile acids (patent RU №2135199, a 61 K 35/78, 27.08.1999). How is that as a drug, adsorbing bile acids enter polifan of 0.3-0.6 g per 1 kg of weight 3-4 times a day until stable reduction of bile acids in the stomach. However, the application of known drug only partially solves the problem of correction of metabolic disorders in patients with chronic renal insufficiency.

Know the treatment for renal failure (patent RU №2172738, a 61 K 31/495, publ. 27.11.1999). The invention relates to derivatives of N-heteroarylboronic General formula I, in which one AND1and3is nitrogen, another is CH, each AND3and4is SN, AG represents a phenyl group which is either not replaced, or has one Deputy, W, X, Y, Z can be nitrogen or a CH group, R1is hydrogen or halogen, and their pharmaceutically acceptable salts.

The task to be solved by the invention consists in expanding the range of drugs used in patients with chronic renal failure (eskay renal failure is characterized by it contains polifan and purified, concentrated soy protein, soy isolates in the following ratio of initial components, wt.%:

Polifan 40,0-60,0

Soy protein isolate 40,0-60,0

Soy products because of its high biological value, hypolipidemic and anti-carcinogenic effects have been used in medicine. Purified concentrated soy protein (soy isolates) are soy products, such as proteins of soybeans SUPRO 760, approved for use in Russia (hygienic conclusion MOH 77.99.9.916.P. 7583.12.99 dated 16.12.1999) and other Last practically deprived of potassium, sodium, phosphorus, carbohydrates, atherogenic lipids and 90% of digestible protein. Additional benefits of soy isolates can serve their relatively low cost and easy option a wide variety of cooking.

The second active ingredient of a drug is non-specific sorbent on the basis of lignin - polifan. It is non-toxic pharmacological drug. The main mechanism of its action is nonspecific sorption in the lumen of the digestive tract exogenous toxins, intermediate products of protein breakdown, ICIE in diarrhea of infectious origin as absorbent microbial cells and products of metabolism. The last mechanism is relevant to patients with ESRD. Polifan has a high sorption capacity with respect to the amino acids and aromatic amines, and also able to adsorb on its surface microbial body.

The clinical efficacy of drugs due to all the known properties of soy protein isolate and strengthened by the presence of the drug Politeama - nespetsificheskogo sorbent isogenic toxins and intermediate degradation products of proteins, fats, carbohydrates, and bile acids. On the one hand, patients with ESRD need protein foods, on the other hand, they have violated the highlight feature of the decay products of food. Receive refined products, Cupro-760, does not contain phosphates, significantly reduces peristalsis, which can be restored with a “gross” foods or taking any supplements. The main requirement for additives, they should be insoluble, i.e. must not contain soluble mineral salts. For example, bran in a large number of contain dietary fiber, but they also contain a significant amount of mineral substances. Microcrystalline cellulose contains no minerals, but it is inert additive.

For the preparation of drug taking pre-calculated number of components, mix and form by known methods in the form of granules or tablets.

Example 1

To assess the impact of drug taking were taken from two groups of patients suffering from diseases of the kidneys (pyelonephritis, diabetic nephropathy, polycystic kidney disease) for 20 people in each group.

The first control group during the year took soy isolate Supro-760 dose of 0.3 g per 1 kg of body weight per day.

The second group during the year was taking drugs at a dose of: isolated soy protein 0.3 g per 1 kg of weight, polifan 0.3 g per 1 kg of body weight per day.

After 12 months, comparisons were made of the main indicators, which are presented in table 1.

From the conducted research it is possible to draw the following conclusions. When comparing therapeutic effect in the first and second group of patients with ESRD is obvious that the application of the proposed drug gives a more pronounced therapeutic effect than the use of pure soy protein isolate, Suliko 10%, total protein from the same patients increased by 25 and 10%, respectively.

At the same time such significant for hemodialysis patients indicators as urea, creatinine and cholesterol in blood of patients in the second group after treatment drugs is significantly lower than in patients in the first group, taking net Supra-760.

Example 2

In the same way as in example 1, but as soy isolate proteins taken soy beans. Comparison of key indicators are presented in table 2.

From research studies can be done the same conclusions as in example 1.

Thus, the drug is non-toxic and highly effective drug is capable of regulating many metabolic disorders that occur in the body, while helping a good evacuation from the bowels of the products of metabolism disorders of metabolism.

Drug for the treatment of chronic renal failure, characterized in that it contains polifan and purified, concentrated soy protein, soy isolates, in the following ratio of initial components, wt.%:

Polifan 40,0-60,0

Soy protein isolate 40,0-60,0

 

Same patents:

The invention relates to new compounds of formula I and Ia in all their stereoisomeric forms or their mixtures in all ratios, and their pharmaceutically acceptable salts, which has antagonistic activity against vitronectin receptor

The invention relates to the creation of medicines in the form of herbal teas, which can be used for treatment of chronic pyelonephritis

The invention relates to medicine, namely to the production of medicines from animal products

The invention relates to medicine, in particular to urology and Nephrology, and for the treatment of acute purulent pyelonephritis

The invention relates to medicine, in particular to oncourology

Pharmaceutical drug // 2213577
The invention relates to medicine

The invention relates to medicine and can be used to treat allergic reactions at a late stage and inflammatory diseases
The invention relates to medicine, in particular, urology

The invention relates to medicine, in particular to urology, andrology and sexual pathology, and can be used in the conditions of policlinic, hospital and sanatorium-resort establishments

The invention relates to the field of veterinary pharmacology, and in particular to means for increasing the resistance of animals

The invention relates to a method for the preparation of phenolic nature of plant materials and can be used in pharmaceutical and food industry

The invention relates to the pharmaceutical industry, and is intended for the prevention and adjunctive therapy in the treatment of diseases of the liver and biliary tract

The invention relates to biochemical pharmacology and can be used in clinical medicine as an anti-inflammatory, wound healing, hemostatic, anti-cancer, deworming and cardiac tonic
The invention relates to medicine, namely to phytotherapeutic remedies for the treatment of patients with gastric ulcer and 12 duodenal ulcer, and chronic gastroduodenitis, including accompanying these diseases chronic cholecystitis

The invention relates to the pharmacy and for the creation of means of plant origin
The invention relates to the field of medicine
The invention relates to the pharmaceutical and medical industry, and in particular to a method for production of biologically active substances from medicinal plants, and for obtaining water-soluble polysaccharides from sunflower grass fragrant violets
The invention relates to the field of medicine, for the establishment of ointments on the basis of plants for the treatment of skin diseases of different etiology

FIELD: medicine, cardiology, phytotherapy, pharmacy.

SUBSTANCE: invention relates to the field in development of an agent of vegetable origin used for improvement of the functional state and prophylaxis of organic alterations in cardiovascular system, in particular, atherosclerosis. The biologically active supplement used for prophylaxis of cardiovascular diseases, in particular, atherosclerosis comprises clover dry extract, haw-thorn flowers powder, ascorbic and nicotinic acids, and accessory substances taken in the definite ratio. The biologically active supplement is made in the form of tablet or capsule. No adverse responses observed in intake of the supplement. The blood cholesterol level was reduced to the normal value in 68% of patients and reducing morbidity with acute respiratory-viral infections has been noticed. In patients with ischemic heart disease with cholesterolemia the improvement of the state is noted on the background of conventional therapy: the moderate reducing the arterial pressure value in its elevation, improved in the state of health, enhanced working capacity, reduced retrosternal pains, ear noise, vertigo, headache.

EFFECT: valuable medicinal properties of supplement.

1 ex

Up!